Acorda therapeutics recognized as one of the best places to work in new york state

Hawthorne, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq: acor) today announced that the company has been recognized as one of the best companies to work for in new york for 2011 based on an independent survey identifying the best places of employment in the state of new york. acorda was ranked third among large companies, defined as employing more than 250 people. this ranking reflected feedback from employees about company culture, benefits and overall job satisfaction. “it’s enormously gratifying for us to be recognized as one of the best places to work in new york. acorda strives to create a work environment that offers our associates a sense of mission, as well as challenging professional opportunities and a great balance of work and fun,” said ron cohen, m.d., acorda’s president and ceo. “as a biotechnology company, acorda develops innovative medicines to improve the lives of the patient communities we serve. our success depends on our ability to attract and retain the best, most creative people possible. by fostering a culture where our associates enjoy their work and find it rewarding, we not only support the success of our own company, but contribute to building a vibrant biotechnology industry in new york state and westchester county.” acorda was among only 50 companies statewide, and four in based in westchester county, to be recognized for this achievement. the best places to work survey was conducted by best companies group (bcg), an independent company that manages best places to work programs on state, regional and national levels. the survey was a partnership between the new york state society for human resource management, the business council of new york and bcg. about acorda therapeutics acorda therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. the company is commercializing and marketing ampyra® (dalfampridine) extended release tablets, 10 mg, in the united states. ampyra is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (ms); this was demonstrated by an improvement in walking speed. ampyra was developed using elan’s matrix drug absorption system (mxdas®) technology and is manufactured by elan based on a supply agreement with acorda. acorda also markets zanaflex capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. the company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain. forward-looking statements this press release includes forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. these statements are subject to risks and uncertainties that could cause actual results to differ materially, including acorda therapeutics' ability to successfully market and sell ampyra in the united states and to successfully market zanaflex capsules; third party payors (including governmental agencies) may not reimburse for the use of ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of ampyra; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of ampyra outside of the united states and our dependence on our collaboration partner biogen idec in connection therewith; competition; failure to protect acorda therapeutics’ intellectual property or to defend against the intellectual property claims of others; the ability to obtain additional financing to support acorda therapeutics' operations; and, unfavorable results from our preclinical programs. these and other risks are described in greater detail in acorda therapeutics' filings with the securities and exchange commission. acorda therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. forward-looking statements made in this release are made only as of the date hereof, and acorda therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
ACOR Ratings Summary
ACOR Quant Ranking